UPMC, the Allegheny Health Network and Penn State University will soon begin hunting for cancer patients who might qualify for a study that will tailor drug treatments to specific genetic abnormalities.

Known as NCI-MATCH, the study hopes to find 1,000 patients around the country who have one of several genetic abnormalities that might respond to certain drug treatments.

“We have all this new technology where we’re able to sequence the DNA of cancers,” said Adam Brufsky, associate director of clinical investigation for the University of Pittsburgh Cancer Institute. From there, he said, researchers can find the mutations that might respond to specific drugs.

Beginning in July, hundreds of institutions will screen about 3,000 cancer patients to find those with specific genetic profiles. The study is aimed at patients whose standard therapy is no longer working, and participants will be allowed to continue receiving treatment as long as their cancer stays at steady levels or decreases.

Advertise with us

The massive trial is part of President Barack Obama’s Precision Medicine Initiative, announced in this year’s State of the Union Address. That initiative will focus on improving the effectiveness of treatment by tailoring it to a patient’s genetic profile.

The University of Pittsburgh Cancer Institute was one of the 30 sites nationwide selected by the National Cancer Institute to participate in the study as a lead academic participating site (LAPS). That means it will be responsible for conducting a large portion of the data analysis after results come in, and will handle more patients than non-LAPS institutions, Dr. Brufsky said.

The Allegheny Health Network, which helped design the study with other experts across the nation, and Penn State will also participate in the trial.

One reason the study is so large, said Shannon Puhalla, a co-principal investigator of one of the study’s branches and physician and breast cancer researcher at Magee-Womens Hospital of UPMC, is because doctors need to examine a large total number of patients to find enough people who have the mutations that can be treated by the selected drugs.

Hannah Schwarz: hschwarz@post-gazette.com, 412-263-3772 or on Twitter @hannahrschwarz